Total Payments
$319,602
2024 Payments
$18,065
Companies
43
Transactions
707
Medicare Patients
8,448
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$214,302 (67.1%)
Travel$47,878 (15.0%)
Consulting$29,918 (9.4%)
Food & Beverage$15,949 (5.0%)
Research$11,444 (3.6%)
Education$111.08 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $131,775 | 52 | 41.2% |
| Honoraria | $82,527 | 39 | 25.8% |
| Travel and Lodging | $47,878 | 137 | 15.0% |
| Consulting Fee | $29,918 | 12 | 9.4% |
| Food and Beverage | $15,949 | 461 | 5.0% |
| Unspecified | $11,444 | 4 | 3.6% |
| Education | $111.08 | 2 | 0.0% |
Payments by Type
General
$308,158
703 transactions
Research
$11,444
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $156,691 | 200 | $0 (2024) |
| Lundbeck LLC | $42,755 | 81 | $0 (2023) |
| MERZ NORTH AMERICA, INC. | $38,281 | 49 | $0 (2020) |
| Adamas Pharmaceuticals, Inc. | $23,767 | 31 | $0 (2021) |
| UCB, Inc. | $15,042 | 45 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $11,834 | 24 | $0 (2024) |
| Kyowa Kirin, Inc. | $5,184 | 11 | $0 (2022) |
| Acorda Therapeutics, Inc | $5,013 | 12 | $0 (2022) |
| MDD US Operations, LLC | $4,626 | 23 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $4,523 | 46 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,065 | 77 | Teva Pharmaceuticals USA, Inc. ($16,767) |
| 2023 | $22,296 | 80 | Teva Pharmaceuticals USA, Inc. ($17,130) |
| 2022 | $26,155 | 79 | Teva Pharmaceuticals USA, Inc. ($25,099) |
| 2021 | $12,021 | 64 | Teva Pharmaceuticals USA, Inc. ($11,242) |
| 2020 | $23,867 | 59 | Adamas Pharmaceuticals, Inc. ($6,705) |
| 2019 | $58,813 | 98 | Teva Pharmaceuticals USA, Inc. ($15,089) |
| 2018 | $90,954 | 128 | Teva Pharmaceuticals USA, Inc. ($50,223) |
| 2017 | $67,432 | 122 | MERZ NORTH AMERICA, INC. ($17,984) |
All Payment Transactions
707 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: Neuropsychiatry | ||||||
| 12/17/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: PAIN | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: Central Nervous System | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Travel and Lodging | Cash or cash equivalent | $7.77 | General |
| Category: Central Nervous System | ||||||
| 11/19/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Immunology | ||||||
| 11/11/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Neurology | ||||||
| 10/21/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: NEUROLOGY | ||||||
| 10/14/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $39.92 | General |
| Category: Neuromodulation | ||||||
| 10/14/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Neuroscience | ||||||
| 10/10/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,688.00 | General |
| Category: Central Nervous System | ||||||
| 10/10/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Travel and Lodging | Cash or cash equivalent | $1,031.72 | General |
| Category: Central Nervous System | ||||||
| 10/10/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $85.05 | General |
| Category: Central Nervous System | ||||||
| 10/01/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Consulting Fee | Cash or cash equivalent | $1,640.00 | General |
| Category: Central Nervous System | ||||||
| 10/01/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Travel and Lodging | Cash or cash equivalent | $400.30 | General |
| Category: Central Nervous System | ||||||
| 10/01/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | Cash or cash equivalent | $24.63 | General |
| Category: Central Nervous System | ||||||
| 09/30/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $37.07 | General |
| Category: Musculoskeletal | ||||||
| 09/30/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Musculoskeletal | ||||||
| 09/29/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $41.33 | General |
| Category: Neuropsychiatry | ||||||
| 09/28/2024 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $132.54 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $58.79 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $7.84 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $1.85 | General |
| Category: Neuropsychiatry | ||||||
| 09/19/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Neurology | ||||||
| 09/15/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Neuromodulation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $10,000 | 3 |
| ACP-103-015 | ACADIA Pharmaceuticals Inc | $1,444 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,817 | 2,335 | $502,704 | $281,534 |
| 2022 | 20 | 2,165 | 2,733 | $563,880 | $310,083 |
| 2021 | 17 | 1,988 | 2,622 | $515,609 | $301,006 |
| 2020 | 15 | 2,478 | 2,649 | $614,466 | $333,086 |
Total Patients
8,448
Total Services
10,339
Medicare Billing
$1.2M
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 169 | 176 | $88,000 | $62,425 | 70.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 211 | 470 | $89,300 | $56,884 | 63.7% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 169 | 176 | $96,800 | $43,888 | 45.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 178 | 342 | $51,300 | $30,995 | 60.4% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 169 | 176 | $26,400 | $19,385 | 73.4% |
| 92652 | Evaluation of brain response to sound for determination of hearing threshold with interpretation and report | Office | 2023 | 169 | 176 | $35,200 | $17,074 | 48.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 96 | 96 | $26,400 | $15,351 | 58.1% |
| 95930 | Measurement of nerve conduction using visual stimulation testing with report | Office | 2023 | 169 | 176 | $35,200 | $10,313 | 29.3% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2023 | 123 | 123 | $18,450 | $4,598 | 24.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 34 | $8,500 | $4,516 | 53.1% |
| 96137 | Administration of psychological or neuropsychological test, each additional 30 minutes | Office | 2023 | 122 | 122 | $5,490 | $4,231 | 77.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 43 | $6,450 | $3,736 | 57.9% |
| 96112 | Administration of developmental test, first hour | Office | 2023 | 23 | 24 | $3,279 | $2,233 | 68.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 42 | 72 | $4,680 | $1,745 | 37.3% |
| 96139 | Administration of psychological or neuropsychological test by technician, each additional 30 minutes | Office | 2023 | 53 | 53 | $2,650 | $1,729 | 65.2% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 53 | 53 | $2,650 | $1,679 | 63.3% |
| 99423 | Online digital evaluation and management service for an established patient for up to 7 days, total time 21 or more minutes | Office | 2023 | 15 | 23 | $1,955 | $752.85 | 38.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 206 | 212 | $103,925 | $69,466 | 66.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 213 | 521 | $98,990 | $67,257 | 67.9% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2022 | 201 | 207 | $113,850 | $46,538 | 40.9% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2022 | 198 | 204 | $30,600 | $22,031 | 72.0% |
| 92652 | Evaluation of brain response to sound for determination of hearing threshold with interpretation and report | Office | 2022 | 201 | 207 | $41,400 | $20,316 | 49.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 130 | 130 | $35,750 | $19,627 | 54.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 117 | 198 | $29,700 | $18,142 | 61.1% |
| 95930 | Measurement of nerve conduction using visual stimulation testing with report | Office | 2022 | 201 | 207 | $41,400 | $11,661 | 28.2% |
About Dr. Jerome Lisk, MD
Dr. Jerome Lisk, MD is a Neurology healthcare provider based in Denton, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821036500.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jerome Lisk, MD has received a total of $319,602 in payments from pharmaceutical and medical device companies, with $18,065 received in 2024. These payments were reported across 707 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($131,775).
As a Medicare-enrolled provider, Lisk has provided services to 8,448 Medicare beneficiaries, totaling 10,339 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Denton, TX
- Active Since 06/03/2006
- Last Updated 01/27/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1821036500
Products in Payments
- AUSTEDO (Drug) $121,002
- NORTHERA (Drug) $42,669
- Austedo XR (Drug) $31,100
- GOCOVRI (Drug) $28,213
- XEOMIN (Biological) $20,296
- Xeomin (Biological) $17,026
- Neupro (Drug) $14,590
- NUPLAZID (Drug) $11,814
- RYTARY (Drug) $8,734
- NOURIANZ (Drug) $5,184
- INBRIJA (Drug) $4,719
- SD809-HD (Drug) $3,694
- KYNMOBI (Drug) $2,157
- DBS IPGs (Device) $2,025
- SD809-TD (Drug) $572.37
- INGREZZA (Drug) $389.33
- Briviact (Drug) $311.12
- DUOPA (Drug) $252.53
- Aimovig (Biological) $236.53
- Deep Brain Stimulation (Device) $197.80
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.